Antiplatelet drugs are most effective for arterial clots that are made largely of platelets. These drugs prevent platelets from clumping and avoid clot formation. To achieve this effect, several of these medications act on receptors and proteins that receive chemical signals and cause cells to bind. Antiplatelet drugs are used as a first-line antithrombotic therapy for the management of acute ischemic syndromes and prevent their recurrence. For instance, aspirin blocks a blood-clotting chemical called thromboxane. The drug is sold under various brand names, such as Ecotrin, Aspir, Bayer, and Easprin. Aspirin is often prescribed to people experiencing a heart attack as the drug can effectively and rapidly inhibit platelet activity and growth of blood clot, thereby maintaining some measure of blood flow.
Global antiplatelet drugs market is estimated to be valued at US$ 2,153.4 million in 2022 and is expected to exhibit a CAGR of 7.8% during the forecast period (2022-2030).
Figure 1. Global Antiplatelet Drugs Market Share (%), by Mode of Administration, 2022
Increasing incidence of cardiovascular diseases is expected to drive growth of the antiplatelet drugs market.
Increasing incidence of cardiovascular diseases is expected to drive the market growth over the forecast period. Increasing prevalence of cardiovascular disorders, growing geriatric population, and sedentary lifestyle are some of the major factors driving the global antiplatelet drugs market growth. Cardiovascular diseases are the principal cause of death in the developed and emerging economies. For instance, in June 2018, according to data published by the American Heart Association, in the U.S. alone, at least 3 to 6 million people had atrial fibrillation, and the numbers are projected to reach ≈6 to 16 million by 2050. In 2020, 3,658 heart transplantations were performed in the U.S. The highest number of heart transplantations were performed in the states of California (496), Texas (302), Florida (288), and New York (250).
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 2,153.4 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 7.8% | 2030 Value Projection: | US$ 3,934.5 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Antiplatelet Drugs Market Share (%), by Region, 2022
Rise in research & development activities for development of antiplatelet drugs is expected to drive the market growth during the forecast period.
Increasing research and development activities by key players in market for development of antiplatelet drugs is expected to drive the market growth over the forecast period. For instance, in April 2022, PhaseBio Pharmaceuticals, Inc., a biopharmaceutical company, announced the complete results from its Phase 2b clinical trial of bentracimab that were presented on April 2 2022 during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22). Bentracimab is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in patients presenting with uncontrolled bleeding or in need of surgery.
Global Antiplatelet Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a positive impact on the global antiplatelet drugs market, owing to its speculated role in protecting against associated incidences with COVID- 19. For instance, in February 2021, according to the National Center for Biotechnology Information, anticoagulants may have positive effects in the treatment of COVID-19, reducing the burden of thrombotic disease and the hyperactivity of coagulation, and may also hold beneficial direct anti-inflammatory effects against sepsis and the development of acute respiratory distress syndrome. The indications for antiplatelet/anticoagulant use (prevention, prophylaxis, therapy) are guided by the clinical context and the COVID-19 severity. Drugs such as remdesivir, lopinavir-ritonavir, interferon, hydroxychloroquine and corticosteroids, have been used in patients with COVID-19, and before against SARS or MERS, showing controversial efficacy. Actually, medical therapies to prevent the effects of the coagulopathy observed in these patients had been suggested for COVID-19. Preliminary data on anticoagulant therapy appear to be associated with better outcomes in moderate and severe COVID-19 patients with signs of coagulopathy (elevated D-dimer and fibrinogen and low anti-thrombin levels), and in those requiring mechanical ventilation.
Global Antiplatelet Drugs Market: Key Developments
In May 2022, Shanghai MicroPort Medical (Group) Co., Ltd. a subsidiary of MicroPort Scientific Corporation, announced that the TARGET Dual antiplatelet therapy study, one of the pivotal post-market clinical studies of the Firehawk Rapamycin Target Eluting Coronary Stent System (Firehawk) completed subject enrollment. The TARGET Dual antiplatelet therapy study is a prospective, multicenter, non-inferiority, randomized, and controlled clinical trial. This study further, in May 21 2022, demonstrated that Firehawk could achieve rapid healing with equal or better safety and efficacy at the world’s lowest dosage — one-third of that of competing products, even when used in high-risk, complex patients.
Global Antiplatelet Drugs Market: Restraint
The major factors that hinder growth of the global antiplatelet drugs market include limitations in efficacy, safety, and tolerability of some antiplatelet drugs. For instance, in July 2018, according to National Center for Biotechnology Information, antiplatelet drugs can irritate lining of the stomach that leads to gastrointestinal side effects such as indigestion and stomach aches. Moreover, patients using these drugs can be more prone to nosebleeds, bruising or bleeding for longer than usual since they reduce the ability of the blood to clot. According to the Journal of Clinical Gastroenterology 2018 report, most spontaneous bleeding in patients treated with antiplatelet drugs occurs in the gastrointestinal tract, with an incidence of 2-3% with dual antiplatelet therapy.
Key Players
Major players operating in the global antiplatelet drugs market include AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company.
Antiplatelet drugs are prescribed to individuals with a history of heart attacks and these drugs aid in reducing reoccurrence of heart attacks. Some of the antiplatelet medications include, aspirin, clopidogrel, prasugrel, and ticagrelor. Aspirin is recommended for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed along with one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients suffering from ACS and for those undergoing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor aid in preventing atherothrombotic events in adult patients with ACS, and those who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.
Market Dynamics
Increasing incidence of chronic diseases such as obesity, diabetes, and cardiovascular diseases (CVDs) is increasing the risk of heart attacks, which in turn is propelling demand for antiplatelet drugs. For instance, according to American Diabetes Association, in 2019, 37.3 million U.S. citizens or 11.3% of the population, had diabetes. Of the 37.3 million adults, nearly 1.9 million U.S. citizens had type 1 diabetes, including about 244,000 children and adolescents. Of the 37.3 million adults with diabetes, 28.7 million were diagnosed, and 8.5 million were undiagnosed. In 2019, 96 million U.S. citizens age 18 and older had prediabetes. 1.4 million U.S. citizens are diagnosed with diabetes every year. According to report by Centers for Disease Control and Prevention, heart disease cost the U.S. about US$229 billion each year from 2017 to 2018. This included the cost of health care services, medicines, and lost productivity due to death. In the U.S. according to the Center for disease control, about 20.1 million adults age 20 and older had Coronary Artery Disease in the year 2019.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients